Predictions
Pfizer Inc.
Start price
Target price
Perf. (%)
€50.01
03.01.22
03.01.22
€78.00
03.01.23
03.01.23
-2.98%
04.01.23
04.01.23
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Undervalued
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€301.55
28.10.22
28.10.22
-
28.10.23
28.10.23
-10.79%
01.01.23
01.01.23
Risky Investment
Johnson & Johnson
Start price
Target price
Perf. (%)
€149.96
28.12.21
28.12.21
-
28.12.22
28.12.22
10.44%
29.12.22
29.12.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Good culture
Top 10 in its market
Biogen Inc.
Start price
Target price
Perf. (%)
€208.25
27.12.21
27.12.21
€215.00
27.12.22
27.12.22
23.82%
28.12.22
28.12.22
Could be worthwhile Investment >10% per year
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€78.94
20.12.22
20.12.22
€90.00
20.12.23
20.12.23
0.23%
24.12.22
24.12.22
Pfizer Inc.
Start price
Target price
Perf. (%)
€52.51
22.12.21
22.12.21
€55.00
22.12.22
22.12.22
-7.45%
23.12.22
23.12.22
Could be worthwhile Investment >10% per year
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€82.42
28.11.22
28.11.22
€100.00
28.11.23
28.11.23
1.15%
10.12.22
10.12.22
Pfizer Inc.
Start price
Target price
Perf. (%)
€48.36
06.12.21
06.12.21
€60.00
06.12.22
06.12.22
-0.12%
06.12.22
06.12.22
Could be worthwhile Investment >10% per year
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€316.75
29.10.22
29.10.22
-
29.11.22
29.11.22
-3.65%
30.11.22
30.11.22
Johnson & Johnson
Start price
Target price
Perf. (%)
€140.70
27.11.21
27.11.21
€160.00
27.11.22
27.11.22
21.35%
28.11.22
28.11.22
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€533.60
09.11.21
09.11.21
€600.00
09.11.22
09.11.22
38.91%
10.11.22
10.11.22
Could be worthwhile Investment >10% per year
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€338.70
07.10.22
07.10.22
€350.00
07.10.23
07.10.23
7.12%
29.10.22
29.10.22
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€59.87
15.05.22
15.05.22
€68.00
15.05.23
15.05.23
32.12%
28.10.22
28.10.22
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Merck & Co. Inc.
Start price
Target price
Perf. (%)
€70.76
26.10.21
26.10.21
€65.00
26.10.22
26.10.22
38.64%
27.10.22
27.10.22
Could be worthwhile Investment >10% per year